IRBS Stock Overview
IR BioSciences Holdings, Inc. operates as a development stage biotechnology company in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
IR Biosciences Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.000001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -99.93% |
| 5 Year Change | -99.50% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| IRBS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -2.5% | -3.2% |
| 1Y | n/a | -3.7% | 19.3% |
Return vs Industry: Insufficient data to determine how IRBS performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how IRBS performed against the US Market.
Price Volatility
| IRBS volatility | |
|---|---|
| IRBS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IRBS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IRBS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | n/a | n/a |
IR BioSciences Holdings, Inc. operates as a development stage biotechnology company in the United States. The company, through its subsidiary, ImmuneRegen BioSciences, Inc., engages in the research and development of therapies in the areas of pulmonary fibrosis, influenza infection, and radiation-induced Neutropenia. It is involved in the development of Homspera, and its derivates Radilex and Viprovex, for human stem cell stimulation, immune system stimulation and anti-infective activity, vaccine adjuvancy, and wound healing.
IR Biosciences Holdings, Inc. Fundamentals Summary
| IRBS fundamental statistics | |
|---|---|
| Market cap | US$17.00 |
| Earnings (TTM) | -US$5.41m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs IRBS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IRBS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$5.41m |
| Earnings | -US$5.41m |
Last Reported Earnings
Dec 31, 2010
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did IRBS perform over the long term?
See historical performance and comparison